Kenneth I Ataga

List of Publications by Year
in descending order

129	7,279	71102	56724
papers	citations	41 h-index	83 g-index

134	134	134	5111
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The nephropathy of sickle cell trait and sickle cell disease. Nature Reviews Nephrology, 2022, 18, 361-377.	9.6	26
2	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. Blood Advances, 2022, 6, 4461-4470.	5.2	5
3	Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia. Blood Advances, 2021, 5, 89-98.	5.2	6
4	Using machine learning to predict rapid decline of kidney function in sickle cell anemia. EJHaem, 2021, 2, 257-260.	1.0	1
5	Haemoglobin response to senicapoc in patients with sickle cell disease: a reâ€analysis of the Phase III trial. British Journal of Haematology, 2021, 192, e129-e132.	2.5	15
6	A pilot study of the effect of rivaroxaban in sickle cell anemia. Transfusion, 2021, 61, 1694-1698.	1.6	1
7	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	4.6	61
8	Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health, 2021, 66, 629338.	2.3	4
9	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	2.5	1
10	Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study. British Journal of Haematology, 2021, 194, e71-e73.	2.5	4
11	Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease. British Journal of Haematology, 2021, 195, 123-132.	2.5	7
12	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. Haematologica, 2021, 106, 1749-1753.	3.5	11
13	Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis. PLoS ONE, 2020, 15, e0229959.	2.5	32
14	Drug Therapies for the Management of Sickle Cell Disease. F1000Research, 2020, 9, 592.	1.6	29
15	Using Machine Learning to Predict Early Onset Acute Organ Failure in Critically Ill Intensive Care Unit Patients With Sickle Cell Disease: Retrospective Study. Journal of Medical Internet Research, 2020, 22, e14693.	4.3	9
16	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	3.5	9
17	A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease. American Journal of Hematology, 2019, 94, E299-E301.	4.1	6
18	Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality. British Journal of Haematology, 2019, 186, 900-907.	2.5	12

#	Article	IF	Citations
19	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
20	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, 2019, 133, 2529-2541.	1.4	51
21	Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study. American Journal of Kidney Diseases, 2019, 74, 47-55.	1.9	37
22	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	5.2	87
23	Machine Learning to Quantitate Neutrophil NETosis. Scientific Reports, 2019, 9, 16891.	3.3	16
24	Plasma metabolomics analysis in sickle cell disease patients with albuminuria â€“ an exploratory study. British Journal of Haematology, 2019, 185, 620-623.	2.5	9
25	Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood, 2019, 133, 615-617.	1.4	71
26	Effect of reninâ€angiotensinâ€aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease. British Journal of Haematology, 2019, 184, 246-252.	2.5	20
27	Hemostatic Aspects of Sickle Cell Disease. , 2019, , 819-842.		0
28	Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia. Blood, 2019, 134, 2308-2308.	1.4	1
29	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. Pediatric Blood and Cancer, 2018, 65, e26993.	1.5	13
30	Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. American Journal of Hematology, 2018, 93, E99-E101.	4.1	4
31	Renal protection by atorvastatin in a murine model of sickle cell nephropathy. British Journal of Haematology, 2018, 181, 111-121.	2.5	14
32	Sickle Cell Nephropathy: Current Understanding of the Presentation, Diagnostic and Therapeutic Challenges. , 2018, , .		3
33	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances, 2018, 2, 3035-3044.	5.2	25
34	Advances in new drug therapies for the management of sickle cell disease. Expert Opinion on Orphan Drugs, 2018, 6, 329-343.	0.8	13
35	Thrombospondinâ€1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. American Journal of Hematology, 2017, 92, E31-E34.	4.1	10
36	Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica, 2017, 102, 626-636.	3.5	97

#	Article	IF	Citations
37	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 429-439.	27.0	599
38	Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease. EBioMedicine, 2017, 24, 26-27.	6.1	1
39	NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PLoS ONE, 2017, 12, e0171067.	2.5	30
40	Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Reviews, 2016, 30, 245-256.	5.7	99
41	Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi. British Journal of Haematology, 2016, 174, 325-329.	2.5	12
42	Sickle Cardiomyopathy. JACC: Cardiovascular Imaging, 2016, 9, 253-254.	5.3	2
43	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Blood, 2016, 128, 1-1.	1.4	16
44	Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia. PLoS ONE, 2016, 11, e0162652.	2.5	27
45	Progression of Chronic Kidney Disease in Sickle Cell Disease. Blood, 2016, 128, 1323-1323.	1.4	3
46	Nutritional Status and Hydroxyurea Use Among Children with Sickle Cell Disease in Malawi. Blood, 2016, 128, 2499-2499.	1.4	0
47	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. Blood, 2016, 128, 2478-2478.	1.4	2
48	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	1.4	0
49	Early Renal Disease in Children with Sickle Cell Disease from Malawi. Blood, 2016, 128, 1316-1316.	1.4	0
50	Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease. American Journal of Hematology, 2015, 90, 691-695.	4.1	43
51	Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease. American Journal of Hematology, 2015, 90, E223-4.	4.1	9
52	Coagulation activation in sickle cell trait: an exploratory study. British Journal of Haematology, 2015, 171, 638-646.	2.5	24
53	Estimated pulmonary artery systolic pressure and sickle cell disease: a metaâ€analysis and systematic review. British Journal of Haematology, 2015, 170, 416-424.	2.5	31
54	The trials and hopes for drug development in sickle cell disease. British Journal of Haematology, 2015, 170, 768-780.	2.5	27

#	Article	IF	Citations
55	Monocytosis is associated with hemolysis in sickle cell disease. Hematology, 2015, 20, 593-597.	1.5	19
56	Lack of Difference in Hepcidin Levels in Sickle Cell Anemia and Sickle Cell Beta Thalassemia. Blood, 2015, 126, 4591-4591.	1.4	2
57	Endothelin-1 Is Associated with Albuminuria and Measures of Vascular Endothelial Dysfunction in Sickle Cell Anemia. Blood, 2015, 126, 983-983.	1.4	12
58	HemobloginA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. Blood, 2015, 126, 3407-3407.	1.4	0
59	Albuminuria Is Associated with Endothelial Dysfunction in Sickle Cell Disease. Blood, 2015, 126, 2186-2186.	1.4	6
60	Establishing Sickle Cell Diagnostics and Characterizing a Pediatric Sickle Cell Disease Cohort in Malawi. Blood, 2015, 126, 2070-2070.	1.4	1
61	Pulmonary hypertension in sickle cell disease: diagnosis and management. Hematology American Society of Hematology Education Program, 2014, 2014, 425-431.	2.5	11
62	Does hydroxyurea prevent pulmonary complications of sickle cell disease?. Hematology American Society of Hematology Education Program, 2014, 2014, 432-437.	2.5	4
63	Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrology Dialysis Transplantation, 2014, 29, 1211-1218.	0.7	64
64	The glomerulopathy of sickle cell disease. American Journal of Hematology, 2014, 89, 907-914.	4.1	100
65	Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology, 2014, 89, 530-535.	4.1	235
66	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	5.6	197
67	Care Seeking for Pain in Young Adults with Sickle Cell Disease. Pain Management Nursing, 2014, 15, 324-330.	0.9	43
68	Hypercoagulability in Sickle Cell Disease: The Importance of the Cellular Component of Blood. Blood, 2014, 124, 4060-4060.	1.4	5
69	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology and Oncology, 2013, 6, 17.	17.0	62
70	Longitudinal study of echocardiographyâ€derived tricuspid regurgitant jet velocity in sickle cell disease. British Journal of Haematology, 2013, 162, 836-841.	2.5	10
71	A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thrombosis Research, 2013, 132, 341-345.	1.7	38
72	The acute chest syndrome of sickle cell disease. Expert Opinion on Pharmacotherapy, 2013, 14, 991-999.	1.8	16

#	Article	IF	Citations
73	Hemostatic abnormalities in sickle cell disease. Current Opinion in Hematology, 2013, 20, 472-477.	2.5	70
74	A doseâ€escalation phase IIa study of 2,2â€dimethylbutyrate (HQKâ€1001), an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2013, 88, E255-60.	4.1	31
75	A Phase I Single Ascending Dose Study Of NKTT120 In Stable Adult Sickle Cell Patients. Blood, 2013, 122, 977-977.	1.4	9
76	Hemostatic Aspects of Sickle Cell Disease. , 2013, , 771-785.		0
77	Preliminary Validity and Reliability of the Sickle Cell Disease Health-Related Stigma Scale. Issues in Mental Health Nursing, 2012, 33, 363-369.	1.2	24
78	A phase 1/2 trial of HQKâ€1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2012, 87, 1017-1021.	4.1	30
79	A potent oral Pâ€selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 536-539.	4.1	72
80	Decades after the cooperative study: A reâ€examination of systemic blood pressure in sickle cell disease. American Journal of Hematology, 2012, 87, E65-8.	4.1	13
81	Hemodynamic Characteristics and Predictors of Pulmonary Hypertension in Patients With Sickle Cell Disease. American Journal of Cardiology, 2012, 109, 1353-1357.	1.6	17
82	Refining the value of secretory phospholipase <scp>A</scp>₂ as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (<scp>PROACTIVE</scp>). British Journal of Haematology, 2012, 157, 627-636.	2.5	42
83	Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease. PLoS ONE, 2012, 7, e29786.	2.5	85
84	Clinical Characteristics Associated with Survival in Adult Sickle Cell Disease. Blood, 2012, 120, 3229-3229.	1.4	4
85	A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate,) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	0
86	A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease.. Blood, 2012, 120, 2102-2102.	1.4	0
87	Hydroxyurea Is Associated with Lower Prevalence of Albuminuria in Adults with Sickle Cell Disease. Blood, 2012, 120, 3211-3211.	1.4	0
88	Association of soluble fmsâ€like tyrosine kinaseâ€1 with pulmonary hypertension and haemolysis in sickle cell disease. British Journal of Haematology, 2011, 152, 485-491.	2.5	21
89	Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vasoâ€occlusive crises in patients with sickle cell disease: a phase III randomized, placeboâ€controlled, doubleâ€blind study of the gardos channel blocker senicapoc (ICAâ€17043). British Journal of Haematology, 2011, 153, 92-104.	2.5	185
90	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 2011, 155, 263-267.	2.5	34

#	Article	IF	Citations
91	A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease. Blood, 2011, 118, 1066-1066.	1.4	1
92	Longitudinal Study of Echocardiographically-Derived Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease. Blood, 2011, 118, 2121-2121.	1.4	0
93	Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease. American Journal of the Medical Sciences, 2010, 339, 266-269.	1.1	49
94	Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood, 2010, 115, 2014-2020.	1.4	41
95	Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fmsâ€like tyrosine kinaseâ€1. European Journal of Haematology, 2010, 85, 257-263.	2.2	51
96	The risks and benefits of longâ€term use of hydroxyurea in sickle cell anemia: A 17.5 year followâ€up. American Journal of Hematology, 2010, 85, 403-408.	4.1	385
97	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology, 2010, 149, 426-435.	2.5	114
98	Systemic Blood Pressure Is Associated with Anemia and Placenta Growth Factor In Sickle Cell Anemia. Blood, 2010, 116, 2644-2644.	1.4	13
99	Increased Red Cell Phosphatidylserine Exposure Correlates with Enhanced Thrombin Generation In Sickle Trait Patients with End Stage Renal Disease. Blood, 2010, 116, 2665-2665.	1.4	3
100	Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia. Blood, 2010, 116, 943-943.	1.4	2
101	Novel therapies in sickle cell disease. Hematology American Society of Hematology Education Program, 2009, 2009, 54-61.	2.5	28
102	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opinion on Investigational Drugs, 2009, 18, 231-239.	4.1	51
103	Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica, 2009, 94, 1481-1484.	3.5	142
104	Fibronectin bridges monocytes and reticulocytes via integrin Î±4Î²1. British Journal of Haematology, 2008, 141, 872-881.	2.5	44
105	Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia. Current Molecular Medicine, 2008, 8, 639-645.	1.3	18
106	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 2008, 111, 3991-3997.	1.4	193
107	Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica, 2008, 93, 20-26.	3.5	162
108	Markers of Coagulation Activation and Inflammation in Sickle Cell Disease and Sickle Cell Trait. Blood, 2008, 112, 4813-4813.	1.4	4

#	Article	IF	Citations
109	Tetrahydrobiopterin (6R-BH4): Novel Therapy for Endothelial Dysfunction in Sickle Cell Disease. Blood, 2008, 112, lba-5-lba-5.	1.4	4
110	Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem. Hematology American Society of Hematology Education Program, 2007, 2007, 91-96.	2.5	166
111	Î²â€Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. British Journal of Haematology, 2007, 139, 3-13.	2.5	188
112	Phase I study of eptifibatide in patients with sickle cell anaemia. British Journal of Haematology, 2007, 139, 612-620.	2.5	51
113	Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology, 2006, 134, 109-115.	2.5	274
114	Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease. Pharmacotherapy, 2006, 26, 1557-1564.	2.6	51
115	Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1626-1631.	2.4	138
116	A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.. Blood, 2006, 108, 685-685.	1.4	8
117	The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease. Journal of Clinical Pharmacology, 2005, 45, 434-445.	2.0	35
118	Progression of Pulmonary Hypertension in Patients with Sickle Cell Disease.. Blood, 2005, 106, 3187-3187.	1.4	3
119	Pulmonary hypertension in sickle cell disease. American Journal of Medicine, 2004, 117, 665-669.	1.5	140
120	Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.. Blood, 2004, 104, 103-103.	1.4	3
121	The Relationship of Pulmonary Hypertension and Survival in Sickle Cell Disease.. Blood, 2004, 104, 1665-1665.	1.4	9
122	Hypercoagulability in sickle cell disease: a curious paradox. American Journal of Medicine, 2003, 115, 721-728.	1.5	185
123	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	7.4	741
124	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2099.	7.4	173
125	Renal cell carcinoma. Current Opinion in Oncology, 2000, 12, 260-264.	2.4	36
126	Renal abnormalities in sickle cell disease. American Journal of Hematology, 2000, 63, 205-211.	4.1	210

#	Article	IF	Citations
127	Bone Marrow Necrosis in Sickle Cell Disease: A Description of Three Cases and a Review of the Literature. American Journal of the Medical Sciences, 2000, 320, 342-347.	1.1	50
128	Multiple myeloma in the breast. , 1999, 61, 203-204.		7
129	Microangiopathic hemolytic anemia associated with metastatic breast carcinoma. , 1999, 61, 254-255.		6